A prospective observational multicenter real world study of the effects of new endocrine therapy for prostate cancer on adrenocortical function

Status

Recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2300068049

Enrollment

Unknown

Registered

2023-02-05

Start date

2023-02-01

Completion date

Unknown

Last updated

2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer

Interventions

abiraterone group:N/A

Apatamide group:N/A

Darotamine group:N/A

enzalutamide group:N/A

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age >=18 years old; 2. Diagnosis of prostate cancer by pathology and progress in imaging assessment (mCRPC, nmCRPC, mHSPC); 3. The patient received the new endocrine therapy for prostate cancer for the first time for more than 1 month; 4. Agree to follow all study procedures and sign an informed consent form; 5. Life expectancy >=3 months.

Exclusion criteria

Exclusion criteria: 1. Previous use of novel endocrine therapies included abiraterone, apatamide, darotamide, and enzalutamide; 2. Ra-223 was previously used; 3. History of previous adrenal disease.

Design outcomes

Primary

Measure	Time frame
Plasma cortisol;ACTH;Proportion of adrenocortical insufficiency caused by new endocrine therapy for prostate cancer;	—

Countries

China

Contacts

Public ContactWang Yongxing

Beijing Anzhen Hospital Affiliated to Capital Medical University

yongxing.wang@ccmu.edu.cn+86 130 0120 6398

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026